Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emricasan in NAFLD with raised transaminases
NCT02077374Phase 2Completed
- Sponsor
- Conatus Pharmaceuticals Inc.
- Start
- Mar 2014
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-alcoholic fatty liver disease (NAFLD) comparing IDN-6556 with Placebo (2 arms). Primary endpoints: Change in Alanine Aminotransferase at Day 28 and Relative Percent Change in Alanine Aminotransferase at Day 28. Started Mar 2014; status: completed.
02
Drugs
emricasan
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT02077374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02077374.